Huw Tanner, Ph.D.

Huw Tanner is the senior vice president of portfolio, program and alliance management at Neumora. Huw brings to Neumora a background in multidisciplinary team leadership spanning a range of discovery and development programs in diverse disease areas. He has held a variety of program leadership roles at early-stage biotech companies including UNITY Biotechnology, Denali Therapeutics and Theravance Biopharma.

Huw has led teams progressing programs through target identification, lead optimization, pre-IND characterization, IND filing, first-in-human and proof-of-concept clinical studies. He is also experienced in creating successful corporate collaborations and alliances for in-licensed and co-developed assets. He is the co-author on more than 20 patent applications and scientific articles and contributed to the invention and progression of two small molecules into oncology clinical studies.

Huw earned his undergraduate MSci degree from Imperial College, London in chemistry, and a Ph.D. in synthetic organic chemistry from the University of Cambridge, UK before moving to California to become a Merck Sharpe Dohme postdoctoral fellow in organic chemistry at the University of California, Irvine.